Novo Nordisk NN6535-4725
Back to Drug Development Trials
![]()
Drug Development Trials
About the trial
A Phase 3A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer’s Disease (EVOKE Plus).
